Knight Therapeutics Inc. places No. 90 on The Globe and Mail’s fifth-annual ranking of Canada’s Top Growing Companies

Article content

MONTREAL, Oct. 02, 2023 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (TSX:GUD) (“Knight” or “the Company”) is pleased to announce it placed No. 90 on the 2023 Report on Business ranking of Canada’s Top Growing Companies.

Canada’s Top Growing Companies ranks Canadian companies on three-year revenue growth. Knight earned its spot with three-year growth of 515%.

Article content

“We are honoured to be recognized as one of Canada’s Top Growing Companies for a third year in a row,” said Samira Sakhia, President and Chief Executive Officer of Knight. “Our team’s exceptional performance ensures Knight’s ongoing success to build a leading pan-American (ex-US) specialty pharmaceutical company. We are proud to be a Canadian born business with operations across 11 countries and two continents, and we will continue to grow while bringing high-quality products that bring innovation and value to our markets in Canada and Latin America.”

Article content

Canada’s Top Growing Companies is an editorial ranking that was launched in 2019. It aims to celebrate the boldest entrepreneurial achievement by identifying and bringing the accomplishments of innovative businesses in Canada to the forefront. To qualify for this voluntary program; companies had to complete an in-depth application process and fulfil requirements. In total, 425 companies earned a spot on this year’s ranking.

The full list of 2023 winners along with editorial coverage is published in the October issue of Report on Business magazine. The list is out now and online here.

“Canada’s Top Growing Companies acknowledges the drive and ingenuity displayed by Canadian business,” says Dawn Calleja, Editor of Report on Business magazine. “This year’s ranking serves as an inspiration for future business owners.”

“This year’s Report on Business magazine’s list of Top Growing Companies shows how innovative ideas always rise to the top, perhaps even more so in times of uncertainty,” says Andrew Saunders, CEO of The Globe and Mail. “The Globe and Mail congratulates this year’s winners for meeting and surpassing those economic challenges.”

Article content

Article content

About The Globe and Mail

The Globe and Mail is Canada’s foremost news media company, leading the national discussion and causing policy change through brave and independent journalism since 1844. With our award-winning coverage of business, politics and national affairs, The Globe and Mail newspaper reaches 6.2 million readers every week in our print or digital formats, and Report on Business magazine reaches 2.7 million readers in print and digital every issue. Our investment in innovative data science means that as the world continues to change, so does The Globe. The Globe and Mail is owned by Woodbridge, the investment arm of the Thomson family.

About Knight Therapeutics Inc.

Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America. Knight’s Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. Knight Therapeutics Inc.’s shares trade on TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company’s web site at www.knighttx.com or www.sedar.com.

Article content

Forward-Looking Statement

This document contains forward-looking statements for Knight Therapeutics Inc. and its subsidiaries. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. Knight Therapeutics Inc. considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared but cautions the reader that these assumptions regarding future events, many of which are beyond the control of Knight Therapeutics Inc. and its subsidiaries, may ultimately prove to be incorrect. Factors and risks which could cause actual results to differ materially from current expectations are discussed in Knight Therapeutics Inc.’s Annual Report and in Knight Therapeutics Inc.’s Annual Information Form for the year ended December 31, 2022, as filed on www.sedar.com. Knight Therapeutics Inc. disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information or future events, except as required by law.

Article content